Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Work
Year: 2015
Type: article
Abstract: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity.
Source: New England Journal of Medicine
Institutions Fox Chase Cancer Center, Hospital Universitario Virgen del Rocío, Vanderbilt-Ingram Cancer Center, Breast Cancer Research Foundation, Tennessee Oncology +26 more
Cites: 22
Cited by: 8,693
Related to: 10
FWCI: 434.4
Citation percentile (by year/subfield): 100
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze